Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781911 · ClinicalTrials.gov registry record · Phase 2
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00781911 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 43 participants.
The verdict
NCT00781911, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
Interventions
- BIOLOGICAL Cixutumumab
- DRUG depot octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781911
The ClinicalTrials.gov registry entry for NCT00781911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cixutumumab is the first listed.
NCT00781911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00781911 about?
NCT00781911 is a clinical study titled "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer". Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
What is the current status of trial NCT00781911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2009-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00781911?
The interventions under investigation include: Cixutumumab (BIOLOGICAL), depot octreotide (DRUG).
Who is sponsoring clinical trial NCT00781911?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.